Simultaneous determination of clobazam and its major metabolite in human plasma by a rapid HPLC method.
Mohammadreza Rouini, Yalda H Ardakani, Lida Hakemi, Maryam Mokhberi, Gheise Badri
Index: J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 823(2) , 167-71, (2005)
Full Text: HTML
Abstract
A rapid and specific HPLC method has been developed and validated for simultaneous determination of clobazam, the anticonvulsant agent, and its major metabolite in human plasma. The sample preparation was a liquid-liquid extraction with tuloene yielding almost near 100% recoveries of two compounds. Chromatographic separation was achieved with a Chromolith Performance RP-18e 100 mm x 4.6mm column, using a mixture of a phosphate buffer (pH 3.5; 10mM)-acetonitrile (70:30, v/v), in isocratic mode at 2 ml/min at a detection wave-length of 228 nm. The calibration curves were linear (r(2)>0.998) in the concentration range of 5-450 ng ml(-1). The lower limit of quantification was 5 ng ml(-1) for two compounds studied. The within- and between-day precisions in the measurement of QC samples at four tested concentrations were in the range of 0.89-9.1% and 2.1-10.1% R.S.D., respectively. The developed procedure was applied to assess the pharmacokinetics of clobazam and its major metabolite following administration of a single 10mg oral dose of clobazam to healthy volunteers.
Related Compounds
Related Articles:
2010-11-01
[Leg. Med. (Tokyo.) 12(6) , 300-4, (2010)]
A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam.
2004-12-01
[Brain Dev. 26(8) , 530-4, (2004)]
Analysis of clobazam and its active metabolite norclobazam in plasma and serum using HPLC/DAD.
1996-11-01
[Scand. J. Clin. Lab. Invest. 56(7) , 609-14, (1996)]
Eye rolling as a manifestation of clobazam toxicity in a child with epilepsy.
2006-07-01
[Dev. Med. Child Neurol. 48(7) , 612-5, (2006)]
1989-03-01
[Biomed. Chromatogr. 3(2) , 79-81, (1989)]